# TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma

> **NCT03529448** · PHASE1,PHASE2 · COMPLETED · sponsor: **Grupo Español de Investigación en Neurooncología** · enrollment: 33 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** TN-TC11G
- **DRUG:** Temozolomide Oral Product
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT03529448
- **Lead sponsor:** Grupo Español de Investigación en Neurooncología
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-18
- **Primary completion:** 2025-11-13
- **Final completion:** 2025-11-13
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2026-02-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03529448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03529448, "TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03529448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*